Synthetic Chemical Software incorporates latest industry standard chemical taxonomony.
Share:
Press Release Summary:
Catering to needs of synthetic chemists, Prous Science Integrity integrates biological, chemical, and pharmacological information on compounds with demonstrated biological activity, synthesis intermediates, and patent family records. Organic Synthesis Knowledge Area allows retrieval of intermediates and reagents as well as synthesis schemes, while visualizations and filtering methods, along with InChIs industry standard chemical taxonomony, promote insight for research approaches.
Original Press Release:
Thomson Reuters Launches New Developments to Support Synthetic Chemists
PHILADELPHIA and LONDON, Aug. 13 -- Thomson Reuters today announced the newest release of Prous Science Integrity developed in response to demand from synthetic chemists in pharmaceutical and fine chemical companies.
The redesigned Organic Synthesis Knowledge Area within Prous Science Integrity allows researchers to directly retrieve intermediates and reagents, as well as synthesis schemes, to pinpoint key characteristics of synthesis route components in seconds. New visualizations and filtering methods plus incorporation of the latest industry standard chemical taxonomony (InChIs) enable new research approaches that save time and provide insights. All these new capabilities can be applied to the foundation of 19,000 schemes of synthesis and 85,000+ structure-searchable intermediates that make Prous Science Integrity a powerful resource to synthetic chemists in the pharmaceuticals and fine chemicals industries.
Pharmaceutical synthetic chemists will value this improved support to easily identify competitor activity, evaluate newly designed synthetic routes and locate suppliers of selected intermediates, while chemists at fine chemicals companies will be able to identify what new drugs are in development and at what phase, giving them the opportunity to promote their existing chemicals, develop new intermediates or highlight alternative steps in a synthesis scheme.
"Prous Science Integrity is being developed to encompass the new paradigm of translational research," said Josep Prous, Jr., Ph.D., Vice President and Chief Scientific Officer at Thomson Reuters. "The features found in this most recent version support the quality data and innovative functionality that customers have come to expect from Thomson Reuters."
Thomson Reuters will be attending the 238th American Chemical Society's National Meeting and Exposition, August 16-20, 2009 in Washington, DC and ChemOutsourcing, September 14-16, 2009 in Long Branch, NJ. Researchers are encouraged to come and receive a demonstration of the latest changes to Prous Science Integrity.
The upgrade is the first of several planned phases over the next year that will increase the depth and breadth of information and add new features, while continuing to provide the highest quality content.
Prous Science Integrity seamlessly integrates biological, chemical and pharmacological information on more than 300,000 compounds with demonstrated biological activity, plus tens of thousands of synthesis intermediates and over 125,000 patent family records. Updated daily, this unique database is designed to support the drug discovery and development activities for thousands of pharmacologists and medicinal chemists as well as other scientific researchers. Find out more about Prous Science Integrity here.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.
CONTACT: Sue Besaw of Healthcare & Science for Thomson Reuters, +1-215-823-1840, susan.besaw@thomsonreuters.com
